IL207246A0 - Treatment of bladder diseases with a tlr7 activator - Google Patents

Treatment of bladder diseases with a tlr7 activator

Info

Publication number
IL207246A0
IL207246A0 IL207246A IL20724610A IL207246A0 IL 207246 A0 IL207246 A0 IL 207246A0 IL 207246 A IL207246 A IL 207246A IL 20724610 A IL20724610 A IL 20724610A IL 207246 A0 IL207246 A0 IL 207246A0
Authority
IL
Israel
Prior art keywords
treatment
bladder diseases
tlr7 activator
tlr7
activator
Prior art date
Application number
IL207246A
Other languages
English (en)
Original Assignee
Univ California
Telormedix Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Telormedix Sa filed Critical Univ California
Publication of IL207246A0 publication Critical patent/IL207246A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL207246A 2008-02-07 2010-07-27 Treatment of bladder diseases with a tlr7 activator IL207246A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2699908P 2008-02-07 2008-02-07
PCT/US2009/000771 WO2009099650A2 (en) 2008-02-07 2009-02-06 Treatment of bladder diseases with a tlr7 activator

Publications (1)

Publication Number Publication Date
IL207246A0 true IL207246A0 (en) 2010-12-30

Family

ID=40939077

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207246A IL207246A0 (en) 2008-02-07 2010-07-27 Treatment of bladder diseases with a tlr7 activator

Country Status (12)

Country Link
US (1) US20090202626A1 (https=)
EP (1) EP2259788A4 (https=)
JP (2) JP2011511073A (https=)
KR (1) KR20100137449A (https=)
CN (1) CN102088974A (https=)
AU (1) AU2009210655B2 (https=)
BR (1) BRPI0907907A2 (https=)
CA (1) CA2713438A1 (https=)
EA (1) EA201001264A1 (https=)
IL (1) IL207246A0 (https=)
MX (1) MX2010008697A (https=)
WO (1) WO2009099650A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
ES2552471T3 (es) 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
EP2316032A1 (en) * 2008-08-20 2011-05-04 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
KR101250419B1 (ko) 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제
HUE055286T2 (hu) 2011-04-08 2021-11-29 Janssen Sciences Ireland Unlimited Co Pirimidinszármazékok vírusfertõzések kezelésére
RS57851B1 (sr) 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purinski derivati za tretman viralnih infekcija
DK2812331T3 (en) * 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
LT2906563T (lt) 2012-10-10 2018-06-11 Janssen Sciences Ireland Uc Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2014128189A1 (en) 2013-02-21 2014-08-28 Janssen R&D Ireland 2-aminopyrimidine derivatives for the treatment of viral infections
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
SG11201509520QA (en) 2013-05-24 2015-12-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
BR112015032546B1 (pt) 2013-06-27 2022-05-17 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças
KR102322425B1 (ko) 2013-07-30 2021-11-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
EP3091978B1 (en) * 2014-01-10 2021-08-18 Urogen Pharma Ltd. Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
WO2015104030A1 (en) * 2014-01-10 2015-07-16 Telormedix Sa Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR101729236B1 (ko) * 2015-06-01 2017-04-21 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
AU2017289418B2 (en) 2016-07-01 2021-06-03 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
JP7274415B2 (ja) 2016-09-29 2023-05-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) * 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
ES2947713T3 (es) 2019-06-13 2023-08-17 Hollister Inc Productos de catéter urinario reutilizables
WO2020263859A1 (en) 2019-06-25 2020-12-30 Hollister Incorporated Reusable urinary catheter products
CN112778372B (zh) * 2019-11-11 2025-09-23 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
DK0553202T3 (da) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE19637209B4 (de) * 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
KR100518903B1 (ko) * 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
WO1999024432A1 (fr) * 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
NZ504800A (en) * 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
TR200101943T2 (tr) * 1999-01-08 2002-04-22 3M Innovative Properties Company Bir immun cevap modifayeri ile mukoza ile ilgili durumların tedavisine yönelik formülasyonlar ve metodlar.
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
ATE322494T1 (de) * 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
US6533645B2 (en) * 2000-01-18 2003-03-18 Applied Materials, Inc. Substrate polishing article
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
AU2002212273B2 (en) * 2000-09-15 2007-06-14 Aaron Diamond Aids Research Centre System and method for optimizing drug therapy for the treatment of diseases
AU2002211602A1 (en) * 2000-10-11 2002-04-22 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
ATE348097T1 (de) * 2001-04-09 2007-01-15 Chiron Corp Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
US7157465B2 (en) * 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
DE60206756T2 (de) * 2001-06-29 2006-07-13 CV Therapeutics, Inc., Palo Alto Purin derivate als a2b adenosin rezeptor antagonisten
US7241890B2 (en) * 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
AU2003271064B2 (en) * 2002-09-27 2010-06-17 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound and use thereof
CA2512161A1 (en) * 2003-01-28 2004-08-12 Shanghai Sunway Biotech Co., Ltd Hyperthermia oncolysis co-therapy
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) * 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
KR20060070572A (ko) * 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
WO2005092893A1 (ja) * 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ９置換−８−オキソアデニン化合物
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
WO2006065234A1 (en) * 2004-12-10 2006-06-22 University Of Pittsburgh Use of lipid and hydrogel vehicles for treatment and drug delivery
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
EP1939202A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
WO2007034917A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
EP2029597A4 (en) * 2006-05-31 2011-11-23 Univ California purine analogs
EP2038290B1 (en) * 2006-07-07 2013-09-04 Gilead Sciences, Inc. Modulators of toll-like receptor 7
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2552471T3 (es) * 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
CA2691444C (en) * 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
JP2011500716A (ja) * 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド Ａ３アデノシン受容体アンタゴニスト
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
US8962652B2 (en) * 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011134669A1 (en) * 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
NZ603155A (en) * 2010-04-30 2014-06-27 Telormedix Sa Phospholipid drug analogs
ES2458355T3 (es) * 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US20120083473A1 (en) * 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators

Also Published As

Publication number Publication date
JP2011511073A (ja) 2011-04-07
CN102088974A (zh) 2011-06-08
MX2010008697A (es) 2010-12-07
AU2009210655A1 (en) 2009-08-13
JP2014129425A (ja) 2014-07-10
EA201001264A1 (ru) 2011-04-29
KR20100137449A (ko) 2010-12-30
BRPI0907907A2 (pt) 2015-07-28
WO2009099650A2 (en) 2009-08-13
EP2259788A2 (en) 2010-12-15
WO2009099650A4 (en) 2010-01-14
EP2259788A4 (en) 2011-03-16
WO2009099650A3 (en) 2009-10-22
AU2009210655B2 (en) 2013-08-15
CA2713438A1 (en) 2009-08-13
US20090202626A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
IL207246A0 (en) Treatment of bladder diseases with a tlr7 activator
IL219974A0 (en) Therapeutic compounds and related methods of use
IL200368A0 (en) Treatment of diseases characterized by inflammation
IL208354A0 (en) Methods of treatment
IL215131A0 (en) Methods of treatment using combination therapy
PL2954932T3 (pl) Zastosowanie terapeutyczne diaminofenotiazyn
PL2280717T3 (pl) Środek terapeutyczny dla chorób beztlenowych
PT2435825E (pt) Métodos para o tratamento de doenças
GB0908193D0 (en) Treatment of disease state
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
ZA200905364B (en) Treatment of diseases characterized by inflammation
IL206491A0 (en) Treatment of produce
IL216000A0 (en) Methods of treating hiv patients with anti-fibrotics
ZA201103752B (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
PL2424529T3 (pl) Nowe postępowania terapeutyczne z zastosowaniem centakwiny
HK1151967A (en) Treatment of bladder diseases with a tlr7 activator
GB0805119D0 (en) Treatment of myelination diseases
GB0819941D0 (en) Treatment of energy utilization diseases
AU2014210680B2 (en) Treatment of female stress urinary incontinence
AU2008903921A0 (en) Treatment of diseases using chemotaxis
GB0915802D0 (en) Therapeutic treatments
GB0817859D0 (en) Treatment of proteostatic disease
GB0818371D0 (en) Bladder sphincter pacemaker
GB0801511D0 (en) The treatment of ophthalmic diseases
GB0913300D0 (en) Therapeutic compounds and their use